Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

v3.8.0.1
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2018
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following:

 

    March 31, 2018     December 31, 2017  
Accrued clinical operations and trials costs   $ 3,267,875     $ 2,003,799  
Accrued product development costs     1,484,701       1,255,439  
Accrued compensation     577,116       1,335,672  
Accrued other     568,582       146,609  
Total   $ 5,898,274     $ 4,741,519